Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$1.78M-98.03%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua Mandel-Brehm
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 48
- Beta
- 0.21
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.31
Financials
Revenue
$1.78M-98.0%Net Income
$-33.53M-6535.7%EBITDA
$-33.53M-440.6%Free Cash Flow
$-12.81M-241.0%EPS (diluted)
$-0.58-4213.5%Shares Outstanding (diluted)
57.93M+57.2%Operating Expenses
$15.16MCash & Debt
$87.13MReturn of Capital
$0.00Revenue by Segment (annual)
$294.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.50M | $-80.40M | $-2.65 |
| 2024 | $652.0K | $-51.79M | $-2.66 |
| 2023 | $350.0K | $-49.29M | $-4.07 |
| 2022 | $294.95M | $-32.49M | $-0.90 |
| 2021 | $295.84M | $-27.99M | $0.00 |
| 2020 | $308.59M | $-56.31M | $0.00 |
| 2019 | $366.11M | $-78.77M | $-2.35 |
| 2018 | $363.80M | $18.40M | $0.53 |
| 2017 | $365.91M | $16.62M | $0.47 |
| 2016 | $351.10M | $-7.15M | $-0.20 |
| 2015 | $280.72M | $16.94M | $0.46 |
| 2014 | $250.61M | $16.51M | $0.46 |
| 2013 | $235.90M | $11.80M | $0.34 |
| 2012 | $180.58M | $44.63M | $1.54 |
Valuation
CAMPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+23.08%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·7d ago·Positive
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
CAMP4 to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming inve…
View source ↗ - Newsthenewswire.com·35d ago·Negative
…ial 85% Interest in Stealthwall West Gold Project in Northeastern Québec Vancouver, British Columbia – TheNewswire - August 31, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (“ Canadian GoldCamps ” or the “ Company ”) announces that, further to its news release dated August 18, 2026, it has completed the acquisition of an initial 85% undivided interest in the Stealthwall West Project (the “Project”), located in the Caniapiscau district of northeastern Québec. The acquisitio…
View source ↗ - Newsthenewswire.com·49d ago·Negative
…greement to Acquire Stealthwall West Gold Project in Northeastern Québec Vancouver, British Columbia – TheNewswire - August 18, 2026 — Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to announce that it has entered into a definitive property acquisition and option agreement dated August 17, 2026, with the arm's length vendors of the Stealthwall West Project. Pursuant to the Agreement, the Company proposes to acquire an initial 85% undivided interest in the Stealthwall Wes…
View source ↗ - Newszacks.com·53d ago·Negative
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.
View source ↗
Earnings
Typical surprise -34.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.58 vs $-0.21miss
- Thu, May 7$-0.32 vs $-0.21miss
- Thu, Mar 5$-0.87 vs $-0.31miss
- Thu, Nov 6$-0.55 vs $-0.47miss
- Thu, Aug 14$-0.62 vs $-0.67beat
- Tue, May 13$-0.62 vs $-0.70beat
Estimates and results for CAMP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAMP officers and directors.
- Bought
- $80.1m
- Sold
- $2.5m
23 trades
6 trades
- Gold Kellybought
- Schwab Andrew J.sold
- Schwab Andrew J.sold
- Schwab Andrew J.sold
- Schwab Andrew J.sold
- Schwab Andrew J.sold
- Tardiff Danielsold
- 5am Partners Vi, Llcbought
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CAMP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.